MindWalk Holdings Corp. functions as an innovative bio-native artificial intelligence firm. Its core mission involves leveraging the synergy of AI, comprehensive multi-omics data, and sophisticated laboratory investigations to accelerate the identification and advancement of biological therapeutics. Utilizing its proprietary LensAI platform and HYFT technology, the company forges partnerships with pharmaceutical and biotechnology enterprises. These collaborations are designed to diminish the inherent risks associated with drug development and to unlock new possibilities for treatments. Founded in 1983, the company adopted its current name, MindWalk Holdings Corp., in September 2025, having previously been known as ImmunoPrecise Antibodies Ltd. Its corporate headquarters are located in Austin, Texas.
MindWalk Showcases ReefIQ™ for AI Drug Discovery at AMD Advancing AI
MindWalk unveiled the first public demonstration of its ReefIQ biological context layer for AI drug discovery at AMD’s Advancing AI 2026 event in San Francisco.
The technology reconnects fragmented discovery data into governed, queryable context, running on AMD Instinct compute to support reasoning workflows.
Management noted that its LensAI platform is already in contracted, recurring arrangements with customers, while the team uses the conference to engage new prospects.